- Home
- NXGL vs PMN Comparison
NXGL vs PMN Comparison
Compare NXGL & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | PMN |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 23.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NXGL | PMN |
|---|---|---|
| Price | $1.66 | $8.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $72.67 |
| AVG Volume (30 Days) | ★ 90.4K | 42.9K |
| Earning Date | 11-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,666,000.00 | N/A |
| Revenue This Year | $39.28 | N/A |
| Revenue Next Year | $42.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 73.37 | N/A |
| 52 Week Low | $1.45 | $6.27 |
| 52 Week High | $5.10 | $39.75 |
Technical Indicators
Market Signals| Indicator | NXGL | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 43.76 | 88.71 |
| Support Level | $1.45 | $7.35 |
| Resistance Level | $2.02 | $9.26 |
| Average True Range (ATR) | 0.15 | 0.60 |
| MACD | 0.03 | 0.43 |
| Stochastic Oscillator | 38.60 | 96.99 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.